POLDIP2

Across TCGA pan-cancer cohorts, POLDIP2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated POLDIP2 data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher POLDIP2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated POLDIP2 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where POLDIP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.245	0.529	.001	35	view →
CCRCC	DFS	Quartile	III,IV	0.362	0.886	.005	19	view →
LUAD	OS	Median	III,IV	0.808	0.294	.019	11	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

POLDIP2–PDAC (OS)

Open the PDAC breakdown →